Eisai, Pfizer deal

The partners settled a dispute over Alzheimer's disease (AD) drug Aricept donepezil. Pfizer will return its Japanese rights to Eisai in December 2012 but retains rights to the reversible acetylcholinesterase (AChE) inhibitor in its other territories until July 2022. The partners co-promote Aricept in the U.S., Japan, and parts of Europe, and Pfizer has exclusive rights in certain other countries. In its 1Q09 earnings, Pfizer disclosed that it received a letter from Eisai stating that upon the close of Pfizer's acquisition of Wyeth (NYSE:WYE, Madison, N.J.), Eisai would have the right to terminate the Aricept deal. The Wyeth deal is expected to close this quarter. ...